Methods of enhancing adjuvaticity of vaccine compositions
AssigneeWittycell
InventorVincent Serra
Life of this patent
Estimating the term…
Abstract
The immunogenicity of vaccines is enhanced by co-administering a synthetic glycolipid, designated PBS-57, with the vaccine. PBS-57 has the ability to stimulate both a cell-mediated and humoral immune response. Co-administration of PBS-57 with a vaccine may be used in methods to stimulate one or more of a humoral immune response, a CD4+ T cell response, and a CD8+ cytotoxic T cell response.
Claims20
A method of enhancing the immunogenicity of a vaccine in a subject comprising co-administering, simultaneously or sequentially, a PBS-57 and the vaccine to the subject, wherein the immunogenicity is enhanced relative to a control.
A method of stimulating a humoral immune response to an antigen in a subject comprising co-administering PBS-57 and a vaccine to the subject, wherein the vaccine includes the antigen.
A method of activating CD4+ T lymphocytes in a subject comprising co-administering PBS-57 and a vaccine to the subject, wherein the vaccine comprises an antigen.
A method of activating CD8+ cytotoxic T lymphocytes in a subject comprising co-administering PBS-57 and a vaccine to the subject, wherein the vaccine comprises an antigen.
Dependencies are inferred from the claim text.